CAVA beats Q2 estimates as cyclospora fears fade, analyst upgrade lifts stock
Morgan Stanley upgrade Morgan Stanley upgraded CAVA to overweight, calling it one of the strongest fundamental stories in restaurants. An upgrade from a major bank signals confidence in the business and draws new investor attention, pushing the stock up.
This is a new analyst endorsement that directly lifted CAVA shares and frames the bull case.
FDA cyclospora outbreak investigation The FDA investigated a cyclospora outbreak that hit the fast-casual sector, dragging CAVA and Sweetgreen down. Health scares scare customers away and raise uncertainty, so the stock fell until the issue eased.
This was the main negative force on CAVA during the period and explains the earlier drop.
Q2 earnings beat and guidance affirmed CAVA beat second-quarter revenue and earnings estimates, with same-restaurant sales up 9% and adjusted EBITDA up 30%. It opened 17 net new restaurants and affirmed full-year guidance, showing the growth story is intact and pushing the stock sharply higher.
The earnings beat is the biggest new positive catalyst and confirms the company's fundamentals.
Cyclospora headwinds moderating Jefferies said quarter-to-date trends were better than feared, with cyclospora-related weakness bottoming in mid-to-late July before same-restaurant sales recovered toward mid-single-digit growth. Fears easing removes a cloud over the stock and supports the rebound.
This explains why the earlier negative health-scare pressure reversed and the stock jumped.